Literature DB >> 16582670

Current status and future prospects for new therapies for pulmonary tuberculosis.

Marcus Vinícius Nora de Souza1.   

Abstract

PURPOSE OF REVIEW: Nowadays tuberculosis is becoming a worldwide problem, and according to the World Health Organization, which declared tuberculosis a global health emergency in 1993, each year 8 million people worldwide develop the active disease and almost 3 million die. RECENT
FINDINGS: Due to this problem there is an urgent need for new strategies and drugs to fight against this disease. In this context, this review describes promising new classes of compounds against tuberculosis that are under study, as well as promising drugs that may soon be introduced onto the market. Another subject reported in this review is inhaled therapy, an important route under study for delivering antitubercular drugs directly to the lungs.
SUMMARY: The implications of new drugs and inhaled therapy in tuberculosis treatment are fewer toxic side-effects, improved pharmacokinetics properties, extensive and potent activity against Gram-positive and Gram-negative bacteria, including resistant strains, and a reduction in the total treatment time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16582670     DOI: 10.1097/01.mcp.0000219264.42686.c9

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  2 in total

1.  Biological evaluation of isoniazid derivatives as an anticancer class.

Authors:  Felipe A R Rodrigues; Augusto C A Oliveira; Bruno C Cavalcanti; Claudia Pessoa; Alessandra C Pinheiro; Marcus V N de Souza
Journal:  Sci Pharm       Date:  2013-09-22

2.  Microwave-assisted solution-phase synthesis and DART-mass spectrometric monitoring of a combinatorial library of indolin-2,3-dione schiff bases with potential antimycobacterial activity.

Authors:  Tarek Aboul-Fadl; Hatem A Abdel-Aziz; Adnan Kadi; Pervez Ahmad; Tilal Elsaman; Mohamed W Attwa; Ibrahim A Darwish
Journal:  Molecules       Date:  2011-06-22       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.